Form 4: Akero Therapeutics' Chief Scientific Officer Executes Stock Option and Sells Shares Under 10b5-1 Plan

Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On March 5, 2025, Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, exercised stock options to acquire 12,500 shares of common stock at a price of $21.10 per share.
• Simultaneously, Rolph sold 9,338 shares at a weighted average price of $44.401, with prices ranging from $43.70 to $44.69.
• He also sold 3,162 shares at a weighted average price of $44.90, with prices ranging from $44.70 to $45.27.
• These transactions were executed under a Rule 10b5-1 trading plan established on August 12, 2024.
• Following these transactions, Rolph directly owns 170,237 shares of Akero Therapeutics common stock and holds options for 34,968 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions, which is neutral in sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. It's common for executives to utilize 10b5-1 trading plans to manage their stock holdings and avoid accusations of insider trading.

Comparison to Industry Standards

• Insider trading activity is closely monitored in the pharmaceutical industry, similar to other sectors.
• Companies like Gilead Sciences and Amgen also have executives who regularly file Form 4 documents detailing their stock transactions.
• The use of 10b5-1 trading plans is a standard practice among executives to ensure compliance with securities laws.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates any significant concerns.

Key Dates